Skip to main content
. Author manuscript; available in PMC: 2014 Jun 1.
Published in final edited form as: Mol Cancer Ther. 2013 May 31;12(6):992–1001. doi: 10.1158/1535-7163.MCT-12-0995

Figure 1. BIBF 1120 inhibits primary tumor growth in subcutaneous lung and orthotopic pancreatic cancer xenografts.

Figure 1

A) Chemical structures of BIBF 1120 (first panel) and chemotherapeutics Gemcitabine and Cisplatin (second and third panels). B) The indicted NSCLC cells were injected subcutaneously into mice. Treatment by with vehicle (Control), BIBF 1120 (BIBF, 50 mg/kg, daily), CHEMO (gemcitabine [25 mg/kg 2x/week] + Cisplatin [1 mg/kg 1x/week]) was initiated when average tumor volume reached 100–150 mm3 (n=10/group). Tumor growth curves displaying mean tumor volume +/− SEM and C) mean final tumor weights +/− SEM are shown. D) The indicated pancreatic cancer cells were injected orthotopically into SCID mice. Treatment was initiated 7–10 days post tumor cell injection (TCI). Animals were treated as above with the exception of chemotherapy; gemcitabine was given at 12.5 mg/kg 3x/week. Mean final pancreas weight +/− SEM is shown (n=10/group). *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001 by Dunn’s post-test.